IMM 1.64% 30.0¢ immutep limited

Cheers YDEncouraging early overall survival data with 6 month...

  1. 601 Posts.
    lightbulb Created with Sketch. 839
    Cheers YD
    Encouraging early overall survival data with 6 month landmark analysis of 73% survival rate...

    NSCLC - Second line PD-1/L1 refractory metastatic cancer very difficult to treat.

    Excellent result thus far.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.